AKL identifies secondary metabolites of plant origin with proven efficacy & safety, and which are capable of being synthesized. These synthetic metabolites then undergo standard pharmaceutical clinical development.
AKL’s innovative approach greatly increases the chances of success, while reducing the probability of unexpected side effects.
AKL has identified two isomers which act synergistically and have been combined to create AKL4 [APPA], a patented investigational oral medicine showing great promise in the treatment of inflammatory conditions including osteoarthritis.
APPA has completed a Phase I trial and a Phase 2a 150-patient 28 day dosing placebo-controlled Human efficacy trial of APPA in osteoarthritis of the knee. For more information on the Phase IIa study, please click here.
A 225 patient 90 day Phase IIb is scheduled for late 2023 in the target commercial population.